IFP Advisors’s Inhibikase Therapeutics IKT Stock Holding History

IFP Advisors’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47	Buy	23 +20	+667%	+$36	﹤0.01%	5027
2026 Q1	$5	Buy	+3	New	+$5	﹤0.01%	4994

Other funds holding IKT

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SIC

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

IFP Advisors's IKT Position: Q2 2026 in Review

IFP Advisors increased its Inhibikase Therapeutics (IKT) stake by 667% in Q2 2026, buying an estimated $36 and bringing the position to 23 shares worth $47. The position accounts for ﹤0.01% of the portfolio, ranked #5027.

IFP Advisors first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. 5 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

IFP Advisors held 23 shares of Inhibikase Therapeutics worth $47 as of Q2 2026.
IFP Advisors bought 20 Inhibikase Therapeutics shares in Q2 2026, an estimated $36.
Inhibikase Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5027 holding.
IFP Advisors first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
5 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.